Bio Pharma Dive
MARCH 31, 2022
After several attempts at designing a drug for acute pain, Vertex has a candidate it's ready to take into late-stage testing following two successful Phase 2 studies.
World of DTC Marketing
MARCH 27, 2022
Mental illnesses are common in the United States. Nearly one in five U.S. adults live with a mental illness (52.9 million in 2020). Mental illnesses include many different conditions that vary in severity, ranging from mild to moderate to severe. Suicidal ideation continues to increase among adults in the U.S. 4.58% of adults report having serious thoughts of suicide, an increase of 664,000 people from last year’s dataset.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
MARCH 30, 2022
Report uses input from healthcare professionals to highlight training and support needs, while also warning about departures
Pharma Mirror
MARCH 31, 2022
It all started in March 2020 and it is now Jan 2022. We still can’t declare the COVID pandemic as “finished”. How has the pandemic impacted the field marketing activity of Pharma companies? What should the industry do to prepare for what will definitely be a new world, post-COVID? There were many analysts who, even before the pandemic, were saying that the role of Medical Representatives will reduce.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
MARCH 31, 2022
While a market downturn has weighed on the biotech industry, FDA approvals for drugs from Bristol Myers Squibb, Bluebird bio and Amylyx Pharmaceuticals could help the sector regain its footing.
World of DTC Marketing
MARCH 28, 2022
Oxford researchers say they have confirmed that alcohol is a direct cause of cancer, emphasizing how their findings reinforce the need to lower levels of alcohol consumption in the population for cancer prevention. The question is will the healthcare community do anything about these findings? Worldwide, alcohol is responsible for an estimated 3 million deaths each year, with over 400,000 from cancer.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Mirror
MARCH 31, 2022
The leading European pharmaceutical marketplace now hosts more than 85 000 CTD dossiers for finished dosage formulation products. Compared to 19 600 products at the start of 2021, the product offering has increased fourfold over a single year. As a response to increasing demand, Pipelinepharma will introduce biosimilar drugs into a separate category.
Bio Pharma Dive
MARCH 30, 2022
A drug regimen including Roche's top prospect tiragolumab didn't outperform standard treatment in its first large trial, a setback for therapies aimed at a protein called TIGIT.
World of DTC Marketing
MARCH 31, 2022
The House is preparing to vote on a $35 monthly insulin cap later, but there is stern opposition to the plan, which could cost billions over ten years. Essentially taxpayers would be subsidizing drug company profits for the price of a product that should have come down a long time ago. Under the bill proposed, Medicare beneficiaries and those insured through private plans would pay no more than $35 for a 30-day insulin prescription, or the lesser of $35 or 25% of the plan’s negotiated pric
Pharma Times
MARCH 28, 2022
Digital health boost as new website focuses on dry eye disease, which currently affects one in four people across the UK
Pharma Mirror
MARCH 31, 2022
Symbiosis Pharmaceutical Services Ltd (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile global manufacture of pharmaceuticals, vaccines and biopharmaceuticals including Advanced Therapeutical Medicinal Products (ATMPs), has announced the completion of a £1.3 million collaborative UKRI-funded project as part of the medicines manufacturing challenge.
Bio Pharma Dive
MARCH 30, 2022
The biotech company plans to reduce its workforce by 30%, or by about 65 employees, in the latest example of a gene therapy developer restructuring.
World of DTC Marketing
MARCH 29, 2022
Healthy eating is your recipe for managing diabetes. More than 37 million Americans have diabetes (about 1 in 10), and approximately 90-95% have type 2 diabetes. Type 2 diabetes most often develops in people over age 45, but more and more children, teens, and young adults are also developing it. A study has found that people with type 2 diabetes were at higher risk of developing 57 health conditions than non-diabetics.
Pharma Times
MARCH 31, 2022
In phase 2 trials, the drug reduced ‘OFF time’ which refers to periods of the day when Parkinson’s symptoms recur despite medication
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Mirror
MARCH 29, 2022
Karlsruhe/Germany, Romaco Macofar’s Oftalmica was specially developed for aseptic filling of sterile eye drops, nasal sprays and injectables. Meeting all GMP requirements for safe processing of highly viscous, oily and foaming liquids, the machine additionally offers fast format changes and short cleaning times. The Oftalmica is Romaco Macofar’s latest technology for aseptic filling of sterile eye drops.
Bio Pharma Dive
MARCH 29, 2022
The drugmaker said etrasimod, an experimental medicine acquired via its Arena buyout, improved remission rates in the second of two studies meant to support its approval in ulcerative colitis.
pharmaphorum
MARCH 30, 2022
Data from a massive real-world study of asthma patients has suggested that overuse of inhalers is widespread and leading to an elevated risk of severe exacerbations. The results from the SABINA registry programme in more than a million people with the respiratory disease show that 40% of patients were over-using short-acting beta agonist (SABA) inhalers, which are used on demand to open up the airways.
Pharma Times
MARCH 28, 2022
Collaboration between Babylon Health and tech giant seeks to speed up historically slow patient access to data
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Mirror
MARCH 29, 2022
NIEL, BELGIUM, eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the Belgian eTheRNA group, is introducing a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines. This new LNP service uses eTheRNA’s proprietary lipid libraries and proprietary formulations to facilitate targeted delivery and tailored biodistribution solutions.
Bio Pharma Dive
APRIL 1, 2022
Taysha Gene Therapies is narrowing its research efforts and cutting around 35% of its workforce, the latest in a series of layoffs announced by makers of genetic medicines.
XTalks
MARCH 29, 2022
Jazz Pharmaceuticals has broken ground on a new $100 million manufacturing plant for cannabis-based medicines in the UK. The facility will be constructed in Kent Science Park (KSP) in Sittingbourne, an industrial town in Kent, England. According to a press release from Jazz Pharma, the plant has a planned opening date in 2024 and will welcome 100 new employees.
Pharma Times
APRIL 1, 2022
Study demonstrates ability of the Parsortix system to isolate circulating tumour cells, targeting the metastatic spread of cancer
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Mirror
MARCH 27, 2022
BARCELONA, Spain, More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Almirall S.A. (BME: ALM) announced today at the American Academy of Dermatology (AAD) Annual Meeting. Lebrikizumab, an investigational IL-13 inhibitor, also led to clinically meaningful improvements in itch and other important patient-reported outcomes
Bio Pharma Dive
MARCH 28, 2022
The study setback raises questions over how well a type of genetic medicine can work in adults with central nervous system disorders like ALS.
pharmaphorum
MARCH 31, 2022
University College Dublin spinout Kinesis Health Technologies, which has developed a range of wearable sensors to assess the physical capabilities of patients, has been bought by US company Linus Health for an undisclosed sum. The merger brings together Kinesis’ gait analysis tools with Linus’ digital brain health monitoring technologies, designed to spot diseases like Alzheimer’s before over symptoms develop.
Pharma Times
MARCH 29, 2022
Collaboration will involve the development of new class IgM antibodies with a view to gaining market approval
NY Times
MARCH 30, 2022
Taking these seven steps now can lower your risk and minimize the disruption to your family’s life.
Bio Pharma Dive
MARCH 28, 2022
Accelerate your path to novel, reliable answers with expert-curated biomedical and clinical data.
BioPharma Reporter
MARCH 28, 2022
AstraZeneca's Evusheld has been approved in the EU for the prevention of COVID-19 in adults and teens 12 years and older weighing at least 40 kg.
Pharma Times
APRIL 1, 2022
New technology could reduce finger pricking by 50% while also providing patients with continuous data about blood sugar levels
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
336 
Let's personalize your content